The development of B-cell lymphoma in a patient with psoriasis treated with cyclosporine.
A 67-year-old Nicaraguan man with a history of chronic, severe, recalcitrant psoriasis participated in a multicenter study investigating oral cyclosporine in the treatment of psoriasis. He received cyclosporine for approximately 8 months at doses of 5 mg/kg/day or less. Treatment with cyclosporine was eventually discontinued because of progressive nephrotoxicity. Approximately 7 months after the discontinuation of cyclosporine, the patient developed a mass in the left maxillary sinus extending to the orbit, the palate, and the infratemporal fossa. Pathologic and histochemical analysis of the mass revealed a B-cell lymphoma. The development of a benign lymphocytic infiltrate has been reported in a patient who received cyclosporine therapy for psoriasis; however, to the best of our knowledge, this is the first case in the United States of lymphoma developing in a patient who was treated with cyclosporine for a condition other than organ transplantation.
Koo
J Y
JY
Department of Dermatology, University of California San Francisco Medical Center 94143.
Kadonaga
J N
JN
Wintroub
B V
BV
Lozada-Nur
F I
FI
D000284:Administration, Oral; D000368:Aged; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000139:chemically induced* / Q000175:diagnosis; D008297:Male; D008441:Maxillary Neoplasms / Q000139:chemically induced* / Q000175:diagnosis; D009378:Neoplasms, Multiple Primary / Q000139:chemically induced* / Q000175:diagnosis; D009918:Orbital Neoplasms / Q000139:chemically induced* / Q000175:diagnosis; D010157:Palatal Neoplasms / Q000139:chemically induced* / Q000175:diagnosis; D011565:Psoriasis / Q000188:drug therapy*
D016572:Cyclosporine